Patents by Inventor George Yancopoulos

George Yancopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a VEGF antagonist to treat angiogenic eye disorders
    Patent number: 11730794
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: August 22, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: George Yancopoulos
  • Use of a VEGF antagonist to treat angiogenic eye disorders
    Patent number: 11707506
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: July 25, 2023
    Assignee: Regeneren Pharmaceuticals, Inc.
    Inventor: George Yancopoulos
  • Use of a VEGF antagonist to treat angiogenic eye disorders
    Patent number: 11253572
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: February 22, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: George Yancopoulos
  • Genetically Modified Non-Human Animals And Methods Of Use Thereof
    Publication number: 20210368752
    Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.
    Type: Application
    Filed: May 10, 2021
    Publication date: December 2, 2021
    Inventors: Richard Flavell, Markus Manz, Anthony Rongvaux, Till Strowig, Tim Willinger, Andrew J. Murphy, Sean Stevens, George Yancopoulos
  • USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
    Publication number: 20210308216
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Application
    Filed: June 17, 2021
    Publication date: October 7, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventor: George YANCOPOULOS
  • USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
    Publication number: 20210308217
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Application
    Filed: June 21, 2021
    Publication date: October 7, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventor: George YANCOPOULOS
  • Genetically modified non-human animals and methods of use thereof
    Patent number: 11026408
    Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: June 8, 2021
    Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)
    Inventors: Richard Flavell, Markus Manz, Anthony Rongvaux, Till Strowig, Tim Willinger, Andrew J. Murphy, Sean Stevens, George Yancopoulos
  • DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
    Publication number: 20210139573
    Abstract: The present invention provides dosing regimens of anti-C5 antibodies, such as pozelimab, for treating or preventing C5-associated diseases such as paroxysmal nocturnal hemoglobinuria or CHAPLE disease.
    Type: Application
    Filed: October 23, 2020
    Publication date: May 13, 2021
    Inventors: John Davis, Albert Thomas Dicioccio, Olivier Harari, Kuan-Ju Lin, Andrew Rankin, Ronda Rippley, Jonathan Weyne, George Yancopoulos, Feng Yang, Yi Zhang
  • USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
    Publication number: 20210121524
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Application
    Filed: December 4, 2020
    Publication date: April 29, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventor: George YANCOPOULOS
  • Methods of modifying genes in eukaryotic cells
    Patent number: 10988776
    Abstract: Methods of creating mutations in genomic exons by inserting introns into the genomic exons via homologous recombination. Also, methods are provided for introducing modifications into genomic exons by inserting introns into the genomic exons via homologous recombination such that a mature mRNA transcript produced from a genomic region of the genome comprising the genomic exon does not contain the modification are provided. The methods provide for a rapid method for introducing mutations and/or modifications of any type into a mammalian cell genome.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: April 27, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Aris N. Economides, David M. Valenzuela, Samuel Davis, George Yancopoulos
  • USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
    Publication number: 20210085753
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Application
    Filed: December 4, 2020
    Publication date: March 25, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventor: George YANCOPOULOS
  • Genetically Modified Non-Human Animals And Methods Of Use Thereof
    Publication number: 20200093105
    Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.
    Type: Application
    Filed: September 27, 2019
    Publication date: March 26, 2020
    Inventors: Richard Flavell, Markus Manz, Anthony Rongvaux, Till Strowig, Tim Willinger, Andrew J. Murphy, Sean Stevens, George Yancopoulos
  • Genetically modified non-human animals and methods of use thereof
    Patent number: 10433527
    Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: October 8, 2019
    Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)
    Inventors: Richard Flavell, Markus Manz, Anthony Rongvaux, Till Strowig, Tim Willinger, Andrew J. Murphy, Sean Stevens, George Yancopoulos
  • Genetically Modified Non-Human Animals And Methods Of Use Thereof
    Publication number: 20190082663
    Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.
    Type: Application
    Filed: May 15, 2018
    Publication date: March 21, 2019
    Inventors: Richard Flavell, Markus Manz, Anthony Rongvaux, Till Strowig, Tim Willinger, Andrew J. Murphy, Sean Stevens, George Yancopoulos
  • METHODS OF MODIFYING GENES IN EUKARYOTIC CELLS
    Publication number: 20180371493
    Abstract: Methods of creating mutations in genomic exons by inserting introns into the genomic exons via homologous recombination. Also, methods are provided for introducing modifications into genomic exons by inserting introns into the genomic exons via homologous recombination such that a mature mRNA transcript produced from a genomic region of the genome comprising the genomic exon does not contain the modification are provided. The methods provide for a rapid method for introducing mutations and/or modifications of any type into a mammalian cell genome.
    Type: Application
    Filed: August 29, 2018
    Publication date: December 27, 2018
    Inventors: Aris N. Economides, David M. Valenzuela, Samuel Davis, George Yancopoulos
  • Genetically Modified Non-Human Animals And Methods Of Use Thereof
    Publication number: 20180020647
    Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.
    Type: Application
    Filed: May 17, 2017
    Publication date: January 25, 2018
    Inventors: Richard Flavell, Markus Manz, Anthony Rongvaux, Till Strowig, Tim Willinger, Andrew J. Murphy, Sean Stevens, George Yancopoulos
  • Genetically modified non-human animals and methods of use thereof
    Patent number: 9820476
    Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: November 21, 2017
    Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)
    Inventors: Richard Flavell, Markus Manz, Anthony Rongvaux, Till Strowig, Tim Willinger, Andrew J. Murphy, Sean Stevens, George Yancopoulos
  • Anti-Activin A antibodies and uses thereof
    Patent number: 9718881
    Abstract: The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders characterized by decreased muscle mass or strength, such as sarcopenia, cachexia, muscle injury, muscle wasting/atrophy, cancer, fibrosis, and weight loss. The antibodies of the invention are also useful in combination with GDF8 binding proteins for the treatment of diseases and disorders characterized by decreased muscle mass or strength. The antibodies of the invention are also useful for the prevention, treatment, or amelioration of disorders and diseases caused by, promoted by, exacerbated by, and/or aggravated by Activin A, such as renal fibrosis.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: August 1, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jesper Gromada, Esther Latres, Andrew Murphy, George Yancopoulos, Lori Morton
  • METHODS, COMPOSITIONS AND KITS FOR CELL SPECIFIC MODULATION OF TARGET ANTIGENS
    Publication number: 20170058045
    Abstract: The present invention provides, inter alia, a method for cell-specific modulation of a target antigen. The method comprises contacting a target cell having the target antigen on the surface of the target cell with: (a) first multi-specific antigen-binding polypeptide comprising: (i) a cell-specific antigen binding domain (C1), (ii) a target antigen binding domain (T1); and (b) a second multi-specific antigen-binding polypeptide comprising: (i) a cell-specific antigen binding domain (C2), (ii) a target antigen binding domain (T2); wherein C1 and C2 interact with the same cell-specific antigen, and the cell-specific antigen and the target antigen are on the same target cell. Pharmaceutical compositions and kits thereof are also included in the present invention.
    Type: Application
    Filed: February 20, 2015
    Publication date: March 2, 2017
    Inventors: Jesper GROMADA, Eric SMITH, Andrew MURPHY, Nicholas PAPADOPOULOS, Joel MARTIN, George YANCOPOULOS, Douglas MACDONALD, David BUCKLER
  • GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF
    Publication number: 20150208622
    Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.
    Type: Application
    Filed: September 6, 2013
    Publication date: July 30, 2015
    Inventors: Richard Flavell, Markus Manz, Anthony Rongvaux, Till Strowig, Tim Willinger, Andrew J. Murphy, Sean Stevens, George Yancopoulos